glucagon

Overview

Glucagon is a peptide hormone and protein-coding biomedical entity produced by pancreatic alpha cells. It is a central counter-regulatory hormone in glucose homeostasis, acting primarily to raise blood glucose when levels fall. In physiological terms, glucagon helps maintain energy balance by promoting hepatic glucose output, and it is therefore closely linked to insulin, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) in endocrine control of metabolism.

In biomedical research and therapeutics, glucagon is of interest both as a native hormone and as a pharmacological target within gut-pancreatic peptide signaling. Recent work has examined glucagon in the context of metabolic disorders, obesity, type 2 diabetes, and metabolic dysfunction–associated steatotic liver disease, including combination approaches involving GLP-1 medications, glucagon-like peptide-1 agonist strategies, and dual- or multi-agonist hormone therapy. These studies reflect the growing recognition that glucagon signaling can be leveraged alongside other incretin and pancreatic peptide pathways to influence glycemic control, body weight, and metabolic outcomes.

Focus of Latest Publications

Recent publications have positioned glucagon as a key component of the evolving therapeutic landscape for metabolic disease. A 2026 review on gut-pancreatic peptide signalling described glucagon, together with GIP, amylin, and peptide YY (PYY), as a peptide of particular interest because of its distinct pharmacological benefits and therapeutic promise in metabolic disorders. This framing emphasizes glucagon not only as a classical glucose-raising hormone, but also as a target within broader multi-agonist strategies designed to improve metabolic control.

In a clinical context, glucagon was mentioned alongside GIP and insulin in a study of exenatide-induced endocrine responses in patients receiving basal insulin. Although the publication focus was on GLP-1 biology, the inclusion of glucagon underscores its relevance in studies of incretin-based therapy and insulin-treated diabetes. The same therapeutic ecosystem is reflected in the retatrutide trial design for chronic kidney disease, where retatrutide was described as an agonist of the GIP, GLP-1, and glucagon receptors. The cited background notes that this agent had previously reduced weight and hemoglobin A1c in individuals with obesity and type 2 diabetes, illustrating how glucagon receptor agonism is being incorporated into multi-receptor drug development.

Glucagon was also measured as a biomarker in a dietary intervention study in metabolic dysfunction–associated steatotic liver disease (MASLD). In that pilot randomized cross-over study, a two-week low glycaemic index, higher fibre diet was associated with reduced body weight and body mass index, as well as decreased interleukin 6 and glucagon levels. This suggests that dietary composition can influence circulating glucagon alongside inflammatory and anthropometric measures, supporting its use as a metabolic readout in nutrition research.

In experimental bioengineering work, glucagon secretion was evaluated in a hydrogel-based co-culture system using islet cells. The study reported that encapsulation did not impair cellular function, with unhindered insulin and glucagon secretion compared with unencapsulated controls in streptozotocin-induced diabetic C57BL/6 mice. This indicates that glucagon remains an important functional endpoint in islet engineering and cell-based diabetes models, where preservation of alpha-cell activity is assessed alongside insulin output.

Key Publications

Jun The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. (Bioscience reports, 2026, PMID 42307179): "Gut-pancreatic peptides such as glucose-dependent insulinotropic polypeptide (GIP), glucagon, amylin, and peptide YY (PYY) are of particular interest due to their distinct pharmacological benefits and therapeutic promise in metabolic disorders."
Jun Exenatide induces an enhanced endogenous glucagon-like peptide-1 secretory response in patients receiving basal insulin. (The Journal of clinical endocrinology and metabolism, 2026, PMID 41604435): "(including glucose-dependent insulinotropic polypeptide [GIP], glucagon, and insulin)."
Jun The effect of a two-week low glycaemic index, higher fibre diet versus high glycaemic index diet on body composition, ectopic lipids, inflammatory biomarkers, gastrointestinal hormones and gut microbiota in metabolic dysfunction-associated steatotic liver disease (MASLD): A pilot randomized cross-over study. (Clinical nutrition ESPEN, 2026, PMID 42044842): "Additionally, the LGI diet resulted in significant reductions in body weight (-1.2 kg, p = 0.018) and body mass index (-0.38 kg/m2, p = 0.017), as well as increased pre-meal appetite scores during the middle of the diet period and decreased interleukin 6; IL-6 (-0.9 pg/mL) and glucagon (-13.7 pg/mL) levels (all p < 0.05)."
May Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease. (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2026, PMID 41160422): "Retatrutide is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors that reduced weight and hemoglobin A1c (HbA1c) in individuals with obesity and type 2 diabetes (T2D)."
Apr Hydrogel-based co-culture and application of two types of islet cells. (PloS one, 2026, PMID 42048373): "Encapsulation did not impair cellular function, as evidenced by unhindered insulin and glucagon secretion compared to unencapsulated controls, in streptozotocin-induced diabetic C57BL/6 mice."